Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
399 studies found for:    "Myelofibrosis"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: SAR302503 (TG101348)
2 Recruiting Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis
Condition: Myelofibrosis
Intervention:
3 Active, not recruiting Lenalidomide for Patients With Myelofibrosis (MF)
Condition: Myelofibrosis
Interventions: Drug: Lenalidomide;   Drug: Prednisone
4 Active, not recruiting Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: Peginterferon alfa-2a
5 Recruiting JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: Ruxolotinib
6 Recruiting Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)
Condition: Myelofibrosis
Interventions: Drug: Panobinostat;   Drug: Ruxolitinib
7 Not yet recruiting Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
Condition: Myelofibrosis
Intervention: Other: Hematopoietic Stem Cell Transplant
8 Completed
Has Results
Ph II Study of Azacitidine in Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: Azacitidine
9 Completed Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: APLIDIN (plitidepsin)
10 Completed
Has Results
A Phase II Study of CC-5013 in Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: CC-5013
11 Terminated
Has Results
Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: bevacizumab (Avastin)
12 Active, not recruiting Allogeneic Stem Cell Transplantation for Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: Busulfan;   Drug: Fludarabine;   Drug: Thymoglobulin (ATG)
13 Recruiting Study of Ruxolitinib for Patients With Myelofibrosis (MF)
Condition: Myelofibrosis
Interventions: Drug: Ruxolitinib;   Behavioral: Questionnaires
14 Recruiting A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: INCB050465;   Drug: Ruxolitinib
15 Completed
Has Results
Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients
Condition: Myelofibrosis
Intervention: Drug: Ruxolitinib
16 Recruiting Quantitative MRI for Myelofibrosis
Condition: Myelofibrosis
Intervention: Procedure: T1 Weighted MRI (magnetic resonance imaging)
17 Active, not recruiting
Has Results
Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: Fludarabine, Melphalan +/- ATG
18 Suspended Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor
Condition: Primary Myelofibrosis
Interventions: Drug: Imetelstat 9.4 milligram/kilogram (mg/kg);   Drug: Imetelstat 4.7 mg/kg
19 Recruiting Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: PIM447;   Drug: Ruxolitinib;   Drug: LEE011
20 Active, not recruiting Study to Compare Busulfan-fludarabine With Thiotepa-fludarabine Regimen in Allogeneic Transplantation for Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: A: Fludarabine + Busulphan;   Drug: B: Fludarabine + Thiotepa

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.